Quantum-Si Incorporated filed a Form 8-K on November 18, 2026, under Regulation FD, disclosing that the company has demonstrated detection of all 20 naturally occurring amino acids in its Proteus™ development program.

Key Highlights

  • Milestone announced: Quantum-Si disclosed it has demonstrated detection of all 20 naturally occurring amino acids in its Proteus™ development program.
  • Disclosure date: The press release was issued on November 18, 2026.
  • Disclosure channel: The announcement was furnished as Exhibit 99.1 to the filing and distributed to the investment community as a press release.
  • Regulatory treatment: The information in Item 7.01 and Exhibit 99.1 is furnished, not filed, and is not deemed incorporated by reference into any registration statement or other filing unless expressly stated.
  • Signing officer: The report was signed by Jeffry Keyes, Chief Financial Officer of Quantum-Si Incorporated.

Quantum-Si Reports Proteus Amino Acid Detection Milestone

Quantum-Si Incorporated (NASDAQ:QSI), a Delaware-incorporated company headquartered at 29 Business Park Drive, Branford, Connecticut, filed a current report on November 18, 2026, disclosing a development milestone in its Proteus™ program. According to the filing, the company issued a press release on that date announcing it has demonstrated detection of all 20 naturally occurring amino acids within the program.

The disclosure was made under Item 7.01 (Regulation FD Disclosure) of the Form 8-K. The filing states that the company "distributes press releases to the investment community to provide updates and summaries of its business." The press release was also furnished as Exhibit 99.1. The filing explicitly states that the information "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934" and is not subject to the liabilities of that section.

The filing includes a forward-looking statements notice, which indicates that certain information "involves risks, uncertainties and assumptions" and that forward-looking statements "may cause our actual plans or results to differ from our assumptions or expectations." The company directed readers to its most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q for a fuller description of risks. The filing also notes that "forward-looking statements speak only as of the date they are made" and the company "expressly disclaim[s] any obligation to update any forward-looking information."

What Was Disclosed

Quantum-Si furnished an 8-K on November 18, 2026, reporting that its Proteus™ development program has demonstrated detection of all 20 naturally occurring amino acids. The accompanying press release was attached as Exhibit 99.1.